FDA Clears Gan & Lee's Investigational New Drug Application To Conduct Phase 2 Head-To-Head Trial Of Bi-Weekly Bofanglutide, For Chronic Weight Management Indication Against Eli Lilly's Tirzepatide
FDA Clears Gan & Lee's Investigational New Drug Application To Conduct Phase 2 Head-To-Head Trial Of Bi-Weekly Bofanglutide, For Chronic Weight Management Indication Against Eli Lilly's Tirzepatide
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.